PARP INHIBITOR
Clinical trials for PARP INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PARP INHIBITOR trials appear
Sign up with your email to follow new studies for PARP INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brain tumor patients may get a survival boost from targeted drug combo
Disease control OngoingThis study tests whether adding olaparib, a drug that blocks DNA repair in cancer cells, to standard chemoradiation can improve survival for people with high-grade gliomas that cannot be fully removed by surgery. The trial has two phases: first, finding the safest dose of olapari…
Matched conditions: PARP INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Lung cancer clue: could a DNA glitch open door to new treatments?
Knowledge-focused OngoingThis study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…
Matched conditions: PARP INHIBITOR
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC